유럽의 신흥 감염증 진단 시장 : 분석 및 예측(2023-2033년)

“The Europe Emerging Infectious Disease Diagnostics Market Expected to Reach $7.85 Billion by 2033.”

Introduction to Europe Emerging Infectious Disease Diagnostics Market

The Europe emerging infectious disease diagnostics market was valued at $4.70 billion in 2023 and is expected to reach $7.85 billion by 2033, growing at a CAGR of 5.28% between 2023 and 2033. The market for diagnosing emerging infectious diseases is experiencing growth due to several key factors. These factors encompass the economic impact of infectious diseases, financial support from governments through funding and partnerships, rising demand for point-of-care and syndromic testing, and advancements in molecular diagnostics technology.

Market Introduction

The European emerging infectious disease diagnostics market is characterized by a diverse array of methods and techniques aimed at identifying and detecting infectious agents swiftly and accurately. This sector plays a crucial role in the timely diagnosis of diseases, facilitating appropriate treatment decisions and public health responses. Within Europe, microbiological culture remains a fundamental method, involving the cultivation of patient specimens on specialized growth media to isolate and identify specific pathogens. This allows for the precise determination of the causative organism and an assessment of its susceptibility to antimicrobial agents. In addition, molecular diagnostics, a rapidly evolving field, is gaining prominence. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are extensively employed, offering highly sensitive and specific pathogen identification, even at low concentrations. With ongoing technological advancements and a growing emphasis on public health, the European market for emerging infectious disease diagnostics is poised for continuous development and innovation.

Market Segmentation:

Segmentation 1: by Application

• Laboratory Testing
• Point-of-Care Testing

Segmentation 2: by Technology

• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies

Segmentation 3: by Type of Infection

• Bacterial
• Viral
• Fungal
• Other Infections

Segmentation 4: by Disease Type

• Respiratory Infections
• Sexually Transmitted Infections (STIs)
• Gastrointestinal Infections
• Other Infections

Segmentation 5: by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users

Segmentation 6: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Europe emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Markets

• 1.1. Market Outlook
  • 1.1.1. Product Definition
  • 1.1.2. Inclusion and Exclusion Criteria
  • 1.1.3. Key Findings
• 1.2. Industry Outlook
  • 1.2.1. Market Overview
    • 1.2.1.1. Timeline of Emerging Technologies for Infectious Disease Diagnostics
    • 1.2.1.2. Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
    • 1.2.1.3. Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
    • 1.2.1.4. Current Market Landscape of Emerging Infectious Disease Diagnostics
    • 1.2.1.5. Future Potential
      • 1.2.1.5.1. CRISPR
      • 1.2.1.5.2. NGS
      • 1.2.1.5.3. INAAT
      • 1.2.1.5.4. Digital PCR (dPCR)
  • 1.2.2. Patent Analysis
    • 1.2.2.1. By Year
    • 1.2.2.2. By Country/Organization
  • 1.2.3. Pipeline Analysis
  • 1.2.4. Impact of COVID-19 on Infectious Disease Diagnostics
    • 1.2.4.1. Post-COVID-19 Scenario: A Paradigm Shift to Home-Based Testing
  • 1.2.5. Supply Chain Analysis
• 1.3. Market Dynamics
  • 1.3.1. Impact Analysis
  • 1.3.2. Drivers
    • 1.3.2.1. Economic Burden of Infectious Diseases
    • 1.3.2.2. Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
    • 1.3.2.3. Increasing Demand for Point-of-Care (POC) and Syndromic Testing
    • 1.3.2.4. Technological Advancements in Molecular Diagnostics
      • 1.3.2.4.1. Isothermal Nucleic Acid Amplification Techniques (INAATs)
      • 1.3.2.4.2. Digital PCR
      • 1.3.2.4.3. CRISPR Technologies
  • 1.3.3. Restraints
    • 1.3.3.1. Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
    • 1.3.3.2. Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
    • 1.3.3.3. Lack of an Established Framework for NGS-based Tests for Infectious Diseases
  • 1.3.4. Opportunities
    • 1.3.4.1. Potential of Molecular Diagnostic Tests in Low-Resource Settings
    • 1.3.4.2. Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance

2. Emerging Infectious Disease Diagnostics Market (by Region)

• 2.1. Europe Emerging Infectious Disease Diagnostics Market
  • 2.1.1. Regulatory Framework
  • 2.1.2. Market Dynamics
    • 2.1.2.1. Impact Analysis
  • 2.1.3. Market Sizing and Forecast
    • 2.1.3.1. Europe Emerging Infectious Disease Diagnostics Market (by Application)
    • 2.1.3.2. Europe Emerging Infectious Disease Diagnostics Market (by Technology)
    • 2.1.3.3. Europe Emerging Infectious Disease Diagnostics Market (by Type of Infection)
    • 2.1.3.4. Europe Emerging Infectious Disease Diagnostics Market (by Disease Type)
    • 2.1.3.5. Europe Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.1. Germany
        • 2.1.3.5.1.1. Market Dynamics
        • 2.1.3.5.1.2. Market Size and Forecast
        • 2.1.3.5.1.2.1. Germany Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.2. U.K.
        • 2.1.3.5.2.1. Market Dynamics
        • 2.1.3.5.2.2. Market Size and Forecast
        • 2.1.3.5.2.2.1. U.K. Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.3. France
        • 2.1.3.5.3.1. Market Dynamics
        • 2.1.3.5.3.2. Market Size and Forecast
        • 2.1.3.5.3.2.1. France Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.4. Italy
        • 2.1.3.5.4.1. Market Dynamics
        • 2.1.3.5.4.2. Market Size and Forecast
        • 2.1.3.5.4.2.1. Italy Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.5. Spain
        • 2.1.3.5.5.1. Market Dynamics
        • 2.1.3.5.5.2. Market Size and Forecast
        • 2.1.3.5.5.2.1. Spain Emerging Infectious Disease Diagnostics Market (by End User)
      • 2.1.3.5.6. Rest-of-Europe
        • 2.1.3.5.6.1. Market Dynamics
        • 2.1.3.5.6.2. Market Size and Forecast
        • 2.1.3.5.6.2.1. Rest-of-Europe Emerging Infectious Disease Diagnostics Market (by End User)

3. Markets - Competitive Benchmarking & Company Profiles

• 3.1. Competitive Landscape
  • 3.1.1. Overview
  • 3.1.2. Corporate Strategies
    • 3.1.2.1. Mergers and Acquisitions
    • 3.1.2.2. Synergistic Activities
    • 3.1.2.3. Business Expansions and Funding
  • 3.1.3. Business Strategies
    • 3.1.3.1. Product Launches/Upgradations/Approvals
• 3.2. Market Share Analysis
• 3.3. Emerging Infectious Disease Diagnostics Ecosystem Active Players
• 3.4. Company Profiles
  • 3.4.1. bioMerieux S.A.
    • 3.4.1.1. Company Overview
    • 3.4.1.2. Role of bioMerieux S.A. in the Emerging Infectious Disease Diagnostics Market
    • 3.4.1.3. Financials
    • 3.4.1.1. Recent Developments
    • 3.4.1.2. Analyst Perspective
  • 3.4.2. DiaSorin S.p.A.
    • 3.4.2.1. Company Overview
    • 3.4.2.2. Role of DiaSorin S.p.A. in the Emerging Infectious Disease Diagnostics Market
    • 3.4.2.3. Financials
    • 3.4.2.4. Recent Developments
    • 3.4.2.5. Analyst Perspective
  • 3.4.3. F. Hoffmann-La Roche Ltd
    • 3.4.3.1. Company Overview
    • 3.4.3.2. Role of F. Hoffmann-La Roche Ltd in the Emerging Infectious Disease Diagnostics Market
    • 3.4.3.3. Financials
    • 3.4.3.4. Recent Developments
    • 3.4.3.5. Analyst Perspective
  • 3.4.4. QIAGEN N.V.
    • 3.4.4.1. Company Overview
    • 3.4.4.2. Role of QIAGEN N.V. in the Emerging Infectious Disease Diagnostics Market
    • 3.4.4.3. Financials
    • 3.4.4.4. Recent Developments
    • 3.4.4.5. Analyst Perspective
  • 3.4.5. Tecan Trading AG
    • 3.4.5.1. Company Overview
    • 3.4.5.2. Role of Tecan Trading AG in the Emerging Infectious Disease Diagnostics Market
    • 3.4.5.3. Financials
    • 3.4.5.4. Recent Developments
    • 3.4.5.5. Analyst Perspective
  • 3.4.6. Siemens Healthineers AG
    • 3.4.6.1. Company Overview
    • 3.4.6.2. Role of Siemens Healthineers AG in the Emerging Infectious Disease Diagnostics Market
    • 3.4.6.3. Financials
    • 3.4.6.4. Recent Developments
    • 3.4.6.5. Analyst Perspective
• 3.5. Company Snapshots
  • 3.5.1. En Carta Diagnostics
    • 3.5.1.1. Company Overview
    • 3.5.1.2. Role of En Carta Diagnostics in the Emerging Infectious Disease Diagnostics Market